APLLTD

Alembic Pharmaceuticals Share Price

₹1,028.65 +115.7 (12.67%)

Stock is trading on High Volume

19 May, 2025 16:40

SIP TrendupStart SIP in APLLTD

Start SIP

Performance

  • Low
  • ₹915
  • High
  • ₹1,050
  • 52 Week Low
  • ₹725
  • 52 Week High
  • ₹1,304
  • Open Price₹919
  • Previous Close₹913
  • Volume3,199,017

Investment Returns

  • Over 1 Month + 21.03%
  • Over 3 Month + 27.11%
  • Over 6 Month + 0.39%
  • Over 1 Year + 6.29%
SIP Lightning

Smart Investing Starts Here Start SIP with Alembic Pharmaceuticals for Steady Growth!

Invest Now

Alembic Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 34.7
  • PEG Ratio
  • -6.6
  • Market Cap Cr
  • 20,220
  • P/B Ratio
  • 4.1
  • Average True Range
  • 30.58
  • EPS
  • 29.14
  • Dividend Yield
  • 1.1
  • MACD Signal
  • 8.15
  • RSI
  • 59.73
  • MFI
  • 56.86

Alembic Pharmaceuticals Financials

Alembic Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,028.65
+ 115.7 (12.67%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹889.82
  • 50 Day
  • ₹884.91
  • 100 Day
  • ₹913.88
  • 200 Day
  • ₹947.87

Resistance and Support

918.15 Pivot Speed
  • R3 947.80
  • R2 939.65
  • R1 926.30
  • S1 904.80
  • S2 896.65
  • S3 883.30

What's your outlook on Alembic Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Alembic Pharmaceuticals Limited, manufactures and markets India Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs). With a strong R&D focus, Alembic derives over $600 million in revenue, with significant contributions from India and the US markets.

Alembic Pharmaceuticals has an operating revenue of Rs. 6,672.09 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 11% is healthy, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and around 5% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 28 which is a POOR score indicating inconsistency in earnings, a RS Rating of 51 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 71 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Alembic Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-06 Audited Results & Final Dividend
2025-02-03 Quarterly Results & Others To consider other business matters. per share(700%)Dividend
2024-11-07 Quarterly Results
2024-08-08 Quarterly Results
2024-05-09 Audited Results & Final Dividend
Date Purpose Remarks
2024-07-15 FINAL Rs.11.00 per share(550%)Final Dividend
2023-07-28 FINAL Rs.8.00 per share(400%)Final Dividend
2022-08-18 INTERIM Rs.10.00 per share(500%)Dividend (Changed Final Dividend as Interim Divided)
View More

Alembic Pharmaceuticals F&O

Alembic Pharmaceuticals Shareholding Pattern

69.67%
9.2%
6.88%
3.94%
0.03%
7.07%
3.21%

About Alembic Pharmaceuticals

  • NSE Symbol
  • APLLTD
  • BSE Symbol
  • 533573
  • Managing Director
  • Mr. Pranav Amin
  • ISIN
  • INE901L01018

Similar Stocks to Alembic Pharmaceuticals

Alembic Pharmaceuticals FAQs

Alembic Pharmaceuticals share price is ₹1,028 As on 19 May, 2025 | 16:26

The Market Cap of Alembic Pharmaceuticals is ₹20219.5 Cr As on 19 May, 2025 | 16:26

The P/E ratio of Alembic Pharmaceuticals is 34.7 As on 19 May, 2025 | 16:26

The PB ratio of Alembic Pharmaceuticals is 4.1 As on 19 May, 2025 | 16:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23